Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium-177 NeoBOMB1 - Advanced Accelerator Applications

Next Previous
Search
Drug Profile

Lutetium-177 NeoBOMB1 - Advanced Accelerator Applications

Alternative Names: 177LuNeoBOMB1; [177Lu] Lu NeoB; [177Lu]-NeoB; AAA 603; lutetium neoB

Latest Information Update: 14 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Erasmus University Rotterdam; National Center for Scientific Research Demokritos
  • Developer Advanced Accelerator Applications; Novartis
  • Class Antineoplastics; Neuropeptides; Oligopeptides; Organometallic compounds; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Bombesin receptor antagonists; Ionising radiation emitters; Neuropeptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II HER2 negative breast cancer; Solid tumours
  • Phase I Breast cancer; Glioblastoma; Prostate cancer
  • No development reported Gastrointestinal stromal tumours

Most Recent Events

  • 29 Jul 2024 Phase-I clinical trials in Prostate cancer (Metastatic disease) in Spain, France (IV) (NCT06379217) (EudraCT2023-505655-43)
  • 21 Jun 2024 Phase-I/II clinical trials in HER2-negative-breast-cancer (Metastatic disease, Combination therapy, Second-line therapy or greater, Late-stage disease) in Singapore (IV) (NCT06247995)
  • 21 Jun 2024 Phase-I/II clinical trials in HER2-negative-breast-cancer (Metastatic disease, Combination therapy, Second-line therapy or greater, Late-stage disease) in Spain (IV) (NCT06247995)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top